IGFBP5 and obesity disorder: As confirmed by protein chip analyses, KY19334 decreased the expression levels of various adipokines such as angiopoietin‐3, DPP4, IGFBP‐5, leptin, resistin and PAI‐1, which are implicated in obesity‐related insulin resistance (Figure 3E).